Deals this week: Pivot Pharmaceuticals, Innovation Pharmaceuticals, Portola Pharmaceuticals
Pivot Pharmaceuticals plans to acquire the worldwide rights to Altum Pharmaceuticals’ BiPhasix Transdermal drug delivery technology.
The company will use the technology to progress the development of its Cannabinoids-based products.
Both Pivot and Altum are biopharmaceutical companies based in Canada.
Innovation Pharmaceuticals plans to raise $30m through the private placement of class A common stock shares.
The US-based biopharmaceutical company plans to use the funds towards general working capital purposes.
Portola Pharmaceuticals has announced an underwritten public offering of six million shares of its common stock, priced at $55 a share to raise $349.25m.
The US-based biopharmaceutical company plans to use the funds towards the commercial launch of its Bevyxxa and andexanet alfa products in the US.
Chinese pharmaceutical company Dali Pharmaceutical plans to issue 25 million shares priced at CNY12.58 ($1.94) per share in an initial public offering (IPO) to raise CNY314.5m ($48.38m) in total.
Hunan Jiudian Pharmaceutical has announced an initial public offering (IPO) of 2.934 billion shares.
The Chinese pharmaceutical company plans to list its shares on the Shenzhen Stock Exchange.
Canadian biopharmaceutical company SpecificiT Pharma has secured funding through a seed funding round led by AmorChem.
The funds are meant to be utilised towards the completion of various business activities.